Melatonin is one of the most common over the counter sleep aids in the country, sold in gas stations, grocery stores, and pharmacies without a prescription. Employees who take it before a night shift or a flight often ask the same question before a scheduled screening: will melatonin show up on a drug test. The short answer is no. Melatonin is not a controlled substance, it is not part of any standard federal or workplace drug test panel, and no commercially used immunoassay is built to detect it.
This article explains what melatonin actually is, why it is not included in the substances that workplace and DOT programs screen for, how supplement contamination differs from true cross reactivity, and what an employer or safety sensitive employee should know if a screening result raises a question.
The question comes up more often now than it did a decade ago, largely because melatonin use has grown quickly among shift workers, frequent travelers, and people managing general sleep disruption. Employers who run drug testing programs sometimes hear from employees who assume any supplement carries some risk of showing up on a screen, or who confuse melatonin with prescription sleep medications that do interact with certain panels. Separating the two helps both sides avoid unnecessary confusion at collection time.
What melatonin is and why it is not tested for
Melatonin is a hormone the body produces naturally to regulate the sleep wake cycle. In the United States, synthetic melatonin is sold as a dietary supplement, which means it is regulated by the Food and Drug Administration under a different framework than prescription drugs or controlled substances. The FDA classifies dietary supplements as products intended to supplement the diet, and manufacturers are responsible for ensuring safety without the premarket approval process required for drugs, according to the FDA's dietary supplements program.
Because melatonin is not a controlled substance under the Controlled Substances Act and has no established pattern of misuse tied to workplace impairment, it was never built into the substance panels that federal agencies and most employers use. The National Center for Complementary and Integrative Health describes melatonin as a hormone available as a dietary supplement, generally used short term for sleep issues such as jet lag or shift work adjustment, with a safety profile that is different from the substances covered under federal workplace testing rules.
The National Institutes of Health's MedlinePlus resource on melatonin lists it among natural products people use for sleep, noting it is available without a prescription and describing typical short term use patterns. That classification as a freely available, non prescription sleep aid is consistent across federal health resources, and it is a large part of why melatonin has never been treated the way employers and regulators treat prescription controlled substances such as benzodiazepines or opioids, which do appear on expanded panels because of documented misuse and diversion risk.
What workplace and DOT panels actually screen for
Federal workplace drug testing programs, including those that apply to DOT regulated safety sensitive employees, are built around the Mandatory Guidelines for Federal Workplace Drug Testing Programs published by the Substance Abuse and Mental Health Services Administration. Those guidelines specify the drug classes and cutoff concentrations used in federal testing, and DOT testing under 49 CFR Part 40 follows that same structure. Melatonin has never been part of that substance list, and neither federal agency's guidance references it as an analyte of interest.
| Panel component | Substance class tested | Is melatonin included |
|---|---|---|
| Federal five (DOT panel) | Marijuana, cocaine, opiates, amphetamines, phencyclidine | No |
| Expanded workplace panels (6 to 18 panel) | Adds benzodiazepines, barbiturates, methadone, propoxyphene, MDMA, and similar classes | No |
| Non-DOT specialty panels | Employer selected combinations of the above plus synthetic opioids or designer drugs | No |
| Prescription or OTC medication verification | Handled through the medical review officer process, not the initial panel | Not applicable, melatonin is OTC and not a screened analyte |
Immunoassay test cups and cards work by using antibodies that bind to specific drug classes or their metabolites. Manufacturers design those antibodies around the substances listed in SAMHSA guidelines and employer policies, which is why panels are described as 5 panel, 10 panel, and so on. Melatonin's chemical structure has no reason to trigger any of those antibody reactions, and no employer or laboratory testing program in general workplace use has added it as a target analyte.
Supplement contamination versus true cross reactivity
These two concepts get confused often, and the difference matters for anyone reviewing a nonnegative result.
True cross reactivity happens when a substance's chemical structure is similar enough to a targeted drug class that it binds to the same antibody and produces a presumptive positive on an immunoassay screen, even though the person never took the targeted drug. Certain decongestants, some prescription medications, and specific foods have documented cross reactivity patterns with particular panels. Melatonin does not have a documented cross reactivity pattern with standard drug test antibodies.
Supplement contamination is a different problem entirely. Because dietary supplements are regulated under a framework described on the FDA's dietary supplements program page that does not require the same premarket approval as prescription drugs, product quality can vary between manufacturers. Independent testing has periodically found that some melatonin products contain more or less melatonin than the label states, and in rare cases contain unlisted ingredients. If a contaminated product actually contained a controlled substance as an undisclosed filler, and someone had actually ingested that substance, a screen could reasonably detect the contaminant itself. That is a contamination and adulteration issue with the supplement supply chain, not a cross reactivity effect from melatonin. It underscores why employers should choose supplements from reputable manufacturers and why any unexpected result should always route through confirmation and the medical review officer process rather than assumption in either direction.
What confirmation testing shows
Any initial screen that comes back nonnegative for a real target analyte should go to laboratory confirmation, typically gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry. Confirmation testing identifies the exact molecule present at a quantified concentration. Because melatonin is not a targeted analyte in the first place, it will not appear as a positive result on either the initial screen or the confirmation report. If a donor's screen is nonnegative for an actual panel substance and the donor mentions melatonin use, the medical review officer will still evaluate the confirmed substance on its own merits, since melatonin itself has no plausible mechanism to explain a true positive for a different drug class.
DOT and non-DOT context
For DOT regulated safety sensitive employees, melatonin is not a prohibited substance and is not something a driver, pilot, or other covered employee needs to disclose the way they would disclose a prescription medication tied to a confirmed positive result. It also is not something that requires a medical certificate exception, since it falls outside the drug and alcohol testing rules under Part 40. Non-DOT employers set their own panels and policies, but melatonin's absence from commercially available panels means the practical outcome is the same across DOT and non-DOT programs. Employees who have questions about how a specific medication or supplement interacts with a scheduled test should raise it with the collector or medical review officer at the time of testing rather than guessing about outcomes in advance.
Frequently asked questions
Will taking melatonin cause a false positive on a drug test?
No documented cross reactivity exists between melatonin and the antibodies used in standard workplace or DOT drug test panels. A false positive from melatonin itself would not be expected on a properly administered screen.
Is melatonin a controlled substance?
No. Melatonin is sold in the United States as an over the counter dietary supplement and is not scheduled under the Controlled Substances Act, which is part of why it is not part of standard drug test panels.
Do employers need to test for melatonin?
Melatonin is not part of SAMHSA's federal testing panel or the DOT panel under 49 CFR Part 40, and it is not included in the commercially available multi panel cups and cards employers typically use. Most employers have no reason to add it, since it has no established link to workplace impairment risk in the way federally regulated substances do.
Should I tell the collector I take melatonin before a drug test?
It is generally reasonable to mention any supplement or medication you take at the time of collection, but since melatonin is not a screened substance, it will not affect how the test is interpreted. Disclosure matters most for actual prescription medications tied to a substance the panel does screen for.
Can a contaminated melatonin supplement cause a positive result?
It is theoretically possible if a supplement contains an undisclosed ingredient that is itself a targeted substance, since dietary supplements do not go through the same premarket approval as prescription drugs. This would reflect contamination of that specific product, not a property of melatonin itself, and any nonnegative result should still go through laboratory confirmation and medical review officer evaluation.
Related reading
- DOT vs Non-DOT Drug Testing: What's Actually Different
- SAMHSA and DOT Drug Testing Cutoff Levels Reference Table
American Screening Corporation supplies multi panel drug test cups built around the substance classes that employers and DOT programs actually screen for.
This article is general information only and is not legal or medical advice. Employers and employees should consult qualified counsel or a medical review officer for guidance specific to their situation.
